A Payoneer nonsteroidal topical solution for psoriasis patients based on a novel mechanism of action
Overview
I Derm Pharma is a biotechnology company focused on developing a novel topical therapy, steroid-free, for treating autoimmune skin inflammatory skin diseases such as Psoriasis.
The problem
About 2-3% of the world population suffer from Psoriasis. Psoriasis is a chronic, painful, disabling incurable skin disease, that negatively impacts patients’ quality of life including physical, functional & emotional well-being.
Psoriasis requires continuous, long-term treatment. Existing topical treatments which are mostly steroid-based, cannot be used long-term due to their side- effects and tachyphylaxis. Biologics treatments are expensive, may cause significant side effects, and reduce effectiveness & safety in the long term.
There is an unmet need for a new class of non-steroidal topical therapy, with at least equal efficacy to existing corticosteroids and with a better safety and tolerability profile for effective treatment of inflammatory- immune-related skin disorders cost-effectively.
Our solution
Our innovative solution operates on a unique mechanism of action. our small molecule-based therapeutic is directed to a novel target within the local inflammatory pathways of the skin and effectively modulates inflammatory responses without compromising the immune system. This pioneering approach introduces a previously untapped avenue for addressing skin inflammatory conditions, offering a promising alternative for patients
Market:
Psoriasis affects about 7.5 M people in the US and 1.1 M people in the UK. The Topicals market is about $5B.
Team:
Dr. Sharon Navon PhD, MBA, Co-Founder & CEO.
Sharon earned her Ph.D. from the chemistry faculty at the Technion. She has more than 8 years of experience in managing building & leading large (~30) pharmaceutical R&D teams for the development of peptide APIs. Sharon was responsible for the processes and the analytical package development, ensuring successful implementation at production sites to achieve GMP lots.
Prof. Eli Sprecher, MD, PhD, MBA, co-founder & clinical advisor.
Prof. Sprecher serves as Deputy Director for Research and Development and chairs the Division of Dermatology at the Tel Aviv Sourasky Medical Center. He is Frederick Reiss Professor of Dermatology at the Sackler Medical School, Tel Aviv University. Prof. Sprecher obtained his MD and PhD degrees from the Hebrew University of Jerusalem, and his MBA from Tel Aviv University. He underwent dermatology specialization at Rambam Medical Center and pursued a fellowship at Thomas Jefferson University, Philadelphia. Additionally, he serves as a section editor for the British Journal of Dermatology and is a board member of The European Society for Dermatological Research, along with being a member of the National Israeli Academy for Medical Sciences. Prof. Sprecher has authored over 300 peer-reviewed publications and has been honored with numerous national and international awards
Dr. Ofer Sarig, PhD, co-founder
Dr. Sarig is the Head of the Laboratory of Molecular Dermatology as part of the Division of Dermatology at the Tel Aviv Sourasky Medical Center. He earned both his MSc and PhD degrees from the Weizmann Institute of Science. With over 70 peer-reviewed publications and more than 20 presentations at scientific meetings, Dr. Sarig contributes significantly to dermatology research.
Zohar Gendler, M.Sc , Chairman of the Board
Zohar is managing Partner & CEO of NGT3 VC. Former CEO & director of Beta-O2 Technologies (developed proprietary implantable bio-artificial pancreas). Served as CEO of the Technion Technological Incubator for 11 years. Led the establishment and investment of more than 50 companies, such as Prolor Biotech (sold to OPKO, NYSE: OPK, for $480M), Mazor (NASDAQ: MZOR, sold to Medtronic, $1.6B), ReWalk (NASDAQ: RWLK), Corindus (NASDAQ: CVRS), Regentis, and many others.
Contact:
Sharon Navon (PhD, MBA), Co-Founder & CEO
052 7726521½ sharon@idermpharma.com
Idermpharma.com